Why would hospitals choose Olinvyk over Morphine when Morphine is 15% the cost of Olinvyk?
1. Understand the situation:
Hospitals Require a Positive Margin to Serve Their Communities: For any organization, a positive operating margin is essential for long-term survival. Few organizations can maintain themselves for an extended period when total expenses are greater than total revenues. For hospitals, positive financial margins allow them to invest in new facilities, treatments, and technologies to better care for patients, and to build reserves to meet unexpected expenses or revenue shortfalls. |
2. Define the problem:
Before COVID-19: Compared with other industries, healthcare margins typically have been very thin. Even before COVID-19, a number of U.S. hospitals struggled with negative margins—in other words, they were losing money on operations. In fact the median hospital margin was a very modest 3.5%. |
3. Define objectives:
Positive margins while operating during COVID-19: When the C-19 pandemic emerged, hospitals had to stop all but the most urgent non-COVID care. The result was a dramatic slowdown in the volume of patients and in revenue, while expenses remained high. These broad range of surgeries and medical procedures include those in the accompanying image. Modifying surgical safety protocols including careful screening, dedicated ingress/egress segregation of non-COVID patients, as well as, selecting IV pain management opioids that have superior safety profiles to those products before Olinvyk's availability will enable happier patients during and after their surgeries. |
6. Evaluate alternatives:
Compared to alternatives, Olinvyk lowers or removes the cost burden of adverse events: The results are greater positive operating margins for hospitals, happier patients, and adaption by formulary committees, governmental pass-through designation, and insurer coverage. This is very important for complex patients such as the elderly, obese, or have renal impairment. |
7. Choose best alternative:
Olinvyk is the best alternative: Rapid. analgesia of just 2-5 minutes onset of pain relief, well-characterized safety and tolerability, and IV morphine data included in label or doctors and anesthesiologist. Olinvyk has a broad indication for acute pain and an unrivaled analgesic efficacy. Top surgeries include total knee arthroplasty, colectomy, hernia repair, spine fusion, and C-section. |
8. Implement alternative:
Olinvyk is NOW APPROVED: Rapid. analgesia of just 2-5 minutes onset of pain relief, well-characterized safety and tolerability, and IV morphine data included in label or doctors and anesthesiologist. Olinvyk has a broad indication for acute pain and an unrivaled analgesic efficacy. Top surgeries include total knee arthroplasty, colectomy, hernia repair, spine fusion, and C-section. Trevena is ready to support and assist your Health Organization to implement the use of Olinvyk is a variety of ways, including: - Virtual "on demand" Medical Education programs - Professional societies & congresses - HCP social media - Field directed: live, virtual & email Olinvyk will leverage margins with respiratory and GI safety vs. IV morphine to expand surgical procedures, as well as, cognitive function & additional HECON, with IV opioid efficacy and fast onset. A Medical Science Liaisons in your area is ready to assist you with any of your organization's needs related to Olinvyk! |
Full Circle:This brings us full-circle to the original question:
Why would your hospital choose Olinvyk over Morphine when Morphine is 15% the cost of Olinvyk? More importantly, "How can Olinvyk bring Positive Margins to your organization?" Olinvyk is ready to implement in a variety physician specialties, inpatient & hospital outpatient |
The estimated average cost across procedures for Olinvyk is ~$100/day.
Compelling health economic model of >10x net savings for hospitals!
Compelling clinical data differentiating acute pain profile and head-to-head peer-reviewed clinical evidence versus IV morphine.
Positive Feedback from Formulary Stakeholders
Compelling health economic model of >10x net savings for hospitals!
Compelling clinical data differentiating acute pain profile and head-to-head peer-reviewed clinical evidence versus IV morphine.
Positive Feedback from Formulary Stakeholders
Compelling positive margin for hospitals!
This is especially for complex patients and targeted surgeries.
Robust set of peer-reviewed publications
Olinvyk nonclinical Phase 1 & Phase 2 data in 15 publications
Olinvyk Phase 3 trials & secondary analyses in 7 publications
4 head-to-head studies vs. IV morphine demonstrating IV opioid efficacy and well-characterized safety and tolerability will allow your organization to re-establish max. scheduling of a variety of complex patients and surgery types, including the elderly and obese.
In this COVID-19 operating environment, Olinvyk, offers a clinical utility over IV morphine resulting in a positive benefit-risk analysis.
In simple terms, Olinvyk, in the new standard in surgical pain management for patients that may otherwise be at-risk with morphine due to respiratory and renal dangers, along with other co-morbidities.
The new chemical entity, Olinvyk, is the pathway towards positive margins.
This is especially for complex patients and targeted surgeries.
Robust set of peer-reviewed publications
Olinvyk nonclinical Phase 1 & Phase 2 data in 15 publications
Olinvyk Phase 3 trials & secondary analyses in 7 publications
4 head-to-head studies vs. IV morphine demonstrating IV opioid efficacy and well-characterized safety and tolerability will allow your organization to re-establish max. scheduling of a variety of complex patients and surgery types, including the elderly and obese.
In this COVID-19 operating environment, Olinvyk, offers a clinical utility over IV morphine resulting in a positive benefit-risk analysis.
In simple terms, Olinvyk, in the new standard in surgical pain management for patients that may otherwise be at-risk with morphine due to respiratory and renal dangers, along with other co-morbidities.
The new chemical entity, Olinvyk, is the pathway towards positive margins.